ASNDAscendis Pharma A/S
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- —
- Market cap
- $15.6B
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Takeover score 0 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo—Buybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo—Any vote under 80% support
Buyer economics 0 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo—Bottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedNo$15.6B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$5M netNet sales over $10M in 12 months
Financials
No XBRL financials yet.
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| May 22, 2020 | ORBIMED ADVISORS LLC | SC 13D/A | 4.8% | Passive |
| May 8, 2020 | ORBIMED ADVISORS LLC | SC 13D/A | 5.2% | Passive |
| Mar 5, 2020 | ORBIMED ADVISORS LLC | SC 13D/A | 12.5% | Passive |
| Oct 23, 2019 | VIVO VENTURES VII, LLC | SC 13D/A | 3.3% | Passive |
| Aug 14, 2019 | ORBIMED ADVISORS LLC | SC 13D/A | 7.1% | Passive |
| Mar 12, 2019 | ORBIMED ADVISORS LLC | SC 13D/A | 7.9% | Passive |
| Feb 12, 2019 | Sofinnova Venture Partners IX, L.P. | SC 13D/A | 4.7% | Passive |
| Jan 11, 2019 | Sofinnova Venture Partners IX, L.P. | SC 13D/A | — | Passive |
Insider trading
- Open-market buys, 12 mo
- $777K · 9
- Open-market sells, 12 mo
- $6M · 3
- Net
- −$5M
Pay vs performance
No pay-versus-performance disclosure yet.